Although MET fusions are well-documented oncogenic drivers in malignancies such as renal cell carcinoma, non-small cell lung cancer, colorectal cancer, and breast cancer, their role in thyroid carcinogenesis remains poorly characterized. This evidence concerns the gene MET and breast cancer.